Attention to CAPA Process Worth Effort, FDA Says

The GMP Letter
Closing a corrective and preventive action (CAPA) and opening a new one after the original action failed its effectiveness check may give the appearance of malfeasance, according to an FDA investigator.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $20.00